Norah Lynn Henry, MD, PhD

Lynn Henry
Daniel F Hayes M.D. Breast Cancer Research Professor
Professor of Internal Medicine
Associate Division Chief for Clinical Research
Section Head and Assistant Director for Training, Education and Career Development (TECD) in Cancer Center
Medical School
Available to mentor
Norah Lynn Henry, MD, PhD
Lynn Henry
Professor
  • About
  • Qualifications
  • Center Memberships
  • Recent Publications
  • Manage Your Profile

  • About

    N. Lynn Henry, MD, PhD is a Professor of Internal Medicine and Associate Director for Community Outreach and Engagement for the Rogel Cancer Center. She was formerly Interim Division Chief and section head for breast oncology in the Division of Hematology/Oncology, associate director of Training, Research, and Education for the Rogel Cancer Center, and Co-Director of the Michigan Breast Oncology Quality Consortium. She is also Co-Chair of the Symptom Management and Quality of Life Committee for the SWOG National Cancer Treatment Network research base. She completed her undergraduate training at Louisiana State University, her doctoral degree in structural biology at Stanford University School of Medicine, and her medical degree at Washington University School of Medicine in St Louis, MO. She then completed her internal medicine residency training at Brigham and Women's Hospital in Boston, MA, followed by hematology/oncology fellowship at the University of Michigan. Dr. Henry cares for patients with all types and stages of breast cancer. Her research is focused on toxicity of therapy for patients with breast cancer, including understanding the mechanisms of development of side effects, identifying which patients are likely to tolerate treatment, and examining interventions to manage toxicity. She has received grant funding from the National Cancer Institute, the American Cancer Society, the Damon Runyon Cancer Research Foundation, the V Foundation, the Hope Foundation for Cancer Research, and the Breast Cancer Research Foundation.

    Qualifications

    • Hematology/Oncology Fellowship
      University of Michigan, United States
      2004 - 2007
      Clinical Fellowship
    • Internal Medicine Residency
      Brigham and Women's Hospital, Boston, MA, United States
      2001 - 2004
      Residency
    • MD
      Washington University School of Medicine, 660 S. Euclid, St Louis, Missouri, 63110, United States
      1996 - 2001
    • PhD
      Stanford University School of Medicine, 300 Pasteur Drive, Stanford, California, 94305, United States
      1991 - 1996

    Center Memberships

    • Center Member
      Taubman Institute
    • Center Member
      Institute for Healthcare Policy and Innovation
    • Center Member
      Rogel Cancer Center
    • Center Member
      e-Health and Artificial Intelligence Initiative
    • Center Member
      AI and Digital Health Innovation
    • Center Member
      Center for Global Health Equity

    Recent Publications

    See All Publications
    • Journal Article
      Determining the feasibility of self-administered relaxing acupressure for fatigue among adolescent and young adult cancer survivors.
      Knoerl R, Jardine J, Chugh R, Fecher LA, Henry NL, Joquico M, Karimi Y, Ploutz-Snyder R, Taylor S, Walling E, Zick S. Support Care Cancer, 2026 Jun 24; 34 (7): DOI:10.1007/s00520-026-10917-2
      PMID: 42337155
    • Presentation
      Early Stage Breast Cancer: ASCO Updates
      Henry L. 2026 Jun 28;
    • Proceeding / Abstract / Poster
      A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2– breast cancer and Oncotype recurrence score ≤ 25 (OFSET): NRG-BR009.
      Mamounas EP, Tang G, Puhalla SL, Swain SM, Ganz PA, Henry NL, Cecchini RS, Reid SA, Rastogi P, Geyer CE, White JR, Clark AS, Haddad TC, Vidal GA, Wolmark N. Journal of Clinical Oncology, 2026 May 30; 44 (16_suppl): tps650 - tps650. DOI:10.1200/jco.2026.44.16_suppl.tps650
    • Journal Article
      A risk prediction model for severe, life-threatening, and fatal treatment-related toxicity.
      Unger JM, Henry NL, Fisch MJ, Hershman DL. Journal of Clinical Oncology, 2026 May 29; 44 (16_suppl): 12143 - 12143. DOI:10.1200/jco.2026.44.16_suppl.12143
    • Proceeding / Abstract / Poster
      Associations between self-efficacy and symptom burden in young women with breast cancer initiating endocrine therapy (ET) on SWOG S2010.
      Henry NL, Darke AK, Unger JM, Schott AF, Kumar P, Mazo-Canola M, Sathe CM, Cabrera-Galeana PA, Kengla AT, Fisch MJ, Hershman DL. Journal of Clinical Oncology, 2026 Jun 1; 44 (16): 521 - 521. DOI:10.1200/JCO.2026.44.16_suppl.521
    • Proceeding / Abstract / Poster
      Immune checkpoint inhibitor (ICI) toxicity in a large prospective cohort of patients with solid tumors: The I-CHECKIT study (SWOG S2013).
      Gunturu KS, Unger JM, Hershman DL, Darke AK, Wei AZ, Hu-Lieskovan S, Walshauser MA, Sochat M, Fisch MJ, Henry NL. Journal of Clinical Oncology, 2026 May 29; 44 (16_suppl): 2640 - 2640. DOI:10.1200/jco.2026.44.16_suppl.2640
    • Proceeding / Abstract / Poster
      Phase 2 study of self-acupressure for aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS)
      Henry L, Griffith K, Kozar S, Scheu K, Cobain E, Armstrong J, Secor M, Snyder S, Zick S. 2026 Jun 26;
    • Proceeding / Abstract / Poster
      Post-treatment recovery patterns among patients with early-stage cancer who develop taxane-induced peripheral neuropathy (TIPN): SWOG S1714 (NCT03939481).
      Trivedi MS, Unger JM, Hertz DL, Till C, Brannagan T, Reyes S, Schneider BP, Irvin WJ, Hathaway AR, Vander Woude AC, Gudena VK, Cabrera-Galeana PA, Orsted M, LeBlanc M, Fisch MJ, Henry NL, Hershman DL. Journal of Clinical Oncology, 2026 May 29; 44 (16_suppl): 12117 - 12117. DOI:10.1200/jco.2026.44.16_suppl.12117

    Featured News & Stories

    ribbons in colorful colors lined up next to eachother
    Health Lab

    5-year survival rate has increased for all cancers, according to American Cancer Society

    The American Cancer Society reports that mortality rates have continued to decline since the 1990s. N. Lynn Henry, of Michigan Medicine, answers questions about how factors such as healthy lifestyle choices, early screening and clinical trials have improved cancer survival rates.